Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 17/20 | 0.56 |
| ▸ | TACR2 | P21452 | 6/20 | 0.54 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | PTGFR | P43088 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14009563 | 0.94 | TACR3 (0.58) | TACR3TACR2TRPV4LMNAOPRM1 | |
| SCHEMBL14009546 | 0.91 | TACR3 (0.55) | TACR3TACR2TRPV4OPRM1 | |
| SCHEMBL14009550 | 0.89 | TACR3 (0.59) | TACR3TACR2TRPV4LMNAOPRM1 | |
| SCHEMBL14009556 | 0.89 | TACR3 (0.74) | TACR3TACR2OPRM1 | |
| SCHEMBL5008111 | 0.89 | TACR3 (0.54) | TACR3TACR2LMNAOPRM1PTGFR | |
| SCHEMBL4603824 | 0.87 | TACR3 (0.53) | TACR3TACR2LMNA | |
| SCHEMBL27725819 | 0.86 | TACR3 (0.52) | TACR3TACR2LMNAOPRM1PTGFR | |
| SCHEMBL14009548 | 0.84 | TACR3 (0.62) | TACR3TACR2TRPV4LMNAOPRM1 | |
| SCHEMBL14009533 | 0.83 | TACR3 (0.61) | TACR3TACR2TRPV4LMNAOPRM1 | |
| SCHEMBL14009557 | 0.83 | TACR3 (0.75) | TACR3TACR2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915361-A1 | ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| WO-2007018466-A1 | ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| US-20080287492-A1 | Alkylpyridyl Quinolines as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287492-A1 | Alkylpyridyl Quinolines as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| WO-2007018466-A1 | ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287492-A1 | Alkylpyridyl Quinolines as Nk3 Receptor Modulators | ADORA3, KCNA3, TACR1 | TACR3 12/4885TACR2 9/4885TRPV4 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.